Long-Term Effectiveness of Liraglutide for Weight Management and Glycemic Control in Type 2 Diabetes
Open accessAbstract
Background: Liraglutide is the first glucagon-like peptide-1 receptor agonist (GLP-1 RA) based on the human GLP-1 sequence, with potential weight loss benefits, approved for the treatment of type 2 diabetes (T2D) mellitus. Herein, we aimed to assess the 5-year effectiveness of Liraglutide in the management of weight and glycometabolic control in a Southern Italian cohort of overweight/obese T2D patients, who were naïve to GLP-1 RAs. Patients and Methods: Forty overweight or obese patients treated with Liraglutide at doses up to 1.8 mg/day, in combination with one or more oral antidiabetic agents, were retrospectively assessed at baseline, during, and after 60 months of continuous therapy. Results: After 5 years of Liraglutide treatment, body weight decreased from 92.1 ± 20.5 kg to 87.3 ± 20.0 Kg (p < 0.001), with a mean reduction of 5.0 ± 7.0 Kg and a body mass index (BMI) decrement of −2.0 ± 3.1 Kg/m2. On Spearman’s univariate analysis, change in body weight was correlated with female gender and baseline BMI. Hemoglobin A1c (HbA1c) decreased from 7.9 ± 0.9% at baseline to 7.0 ± 0.7% at the end of the study period (p < 0.001), followed by a significant reduction in fasting plasma glucose. No significant differences emerged in other biochemical parameters, despite a trend toward improvement in lipid profile. Notwithstanding encouraging effects on several markers of cardiovascular disease (CVD), increments in the 5- and 10-year risk for the first atherosclerotic cardiovascular event were documented, as four incident cases of myocardial infarction. Conclusions: Prolonging treatment with Liraglutide can lead to durable benefits in relation to weight and glycemic control, with a greater impact on women. These results extend and corroborate previous observations, suggesting that gender per se may modulate the response to Liraglutide. Despite favorable effects on some established CVD risks factors, the long-term role of Liraglutide in primary prevention of CVD in patients with T2D remains controversial.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Another study with liraglutide concluded that in addition to female sex, a higher baseline BMI was also associated with greater weight loss; in that study female participants were slightly heavier than males at baseline.
“Interestingly enough, another study with liraglutide produced opposing results, as it concluded that in this case, in addition to female sex, a higher baseline BMI was also associated with greater weight loss. It should be noted that in this particular case, the female participants were slightly heavier than the males at the beginning of the study [58].”
From Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care (2022) · cites this paper as [58]
Obese patients have lower GLP-1 responses to oral glucose than individuals of normal weight, irrespective of glycemic status.
“From a diabetes prevention perspective, the GLP-1-releasing effects of PUFAs could be particularly important, given that obese patients have lower GLP-1 responses to oral glucose than individuals of normal weight, irrespective of the glycemic status [52,53].”
From Mediterranean diet nutrients to turn the tide against insulin resistance and related diseases (2020) · cites this paper as [53]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518 · see citing works
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487 · see citing works
Wing, R. R., Lang, W., Wadden, T. A., Safford, M., Knowler, W. C., Bertoni, A. G., Hill, J. O., Brancati, F. L., Peters, A., Wagenknecht, L., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2415 · Cited by 1,828 · see citing works
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · see citing works
Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198 · see citing works
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129 · see citing works
The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56)
STEVENS, R. J., KOTHARI, V., ADLER, A. I., & STRATTON, I. M. (2001) · Clinical Science · doi:10.1042/cs20000335 · Cited by 1,084 · see citing works
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057 · see citing works
Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848 · see citing works
on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835 · see citing works
Marre, M., Shaw, J. E., Brändle, M., Bebakar, W. M. W., Kamaruddin, N. A., Strand, J., Zdravkovic, M. D., Thi, T. D. L., Colagiuri, S., & on behalf of the LEAD‐1 SU study group (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02666.x · Cited by 814 · see citing works
9. Pharmacologic Approaches to Glycemic Treatment: <i>Standards of Medical Care in Diabetes—2019</i>
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s009 · Cited by 739 · see citing works
Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
Nauck, M. A., Vardarli, I., Deacon, C. F., Holst, J. J., & Meier, J. J. (2011) · Diabetologia · doi:10.1007/s00125-010-1896-4 · Cited by 465 · see citing works
GLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans
van Bloemendaal, L., IJzerman, R. G., ten Kulve, J. S., Barkhof, F., Konrad, R. J., Drent, M. L., Veltman, D. J., & Diamant, M. (2014) · Diabetes · doi:10.2337/db14-0849 · Cited by 427 · see citing works
Daousi, C., Casson, I. F., Gill, G. V., MacFarlane, I. A., Wilding, J. P. H., & Pinkney, J. H. (2006) · Postgraduate Medical Journal · doi:10.1136/pmj.2005.039032 · Cited by 351 · see citing works
The importance of weight management in type 2 diabetes mellitus
Wilding, J. P. H. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12384 · Cited by 314 · see citing works
Cardiovascular risk assessment in patients with diabetes
Bertoluci, M. C., & Rocha, V. Z. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0225-1 · Cited by 260 · see citing works
Quantifying importance of major risk factors for coronary heart disease
Pencina, M. J., Navar, A. M., Wojdyla, D., Sanchez, R. J., Khan, I., Elassal, J., D’Agostino, R. B., Peterson, E. D., & Sniderman, A. D. (2019) · Circulation · doi:10.1161/circulationaha.117.031855 · Cited by 247 · see citing works
Gender-specific care of the patient with diabetes: review and recommendations
Legato, M. J., Gelzer, A., Goland, R., Ebner, S. A., Rajan, S., Villagra, V., & Kosowski, M. (2006) · Gender Medicine · doi:10.1016/s1550-8579(06)80202-0 · Cited by 225 · see citing works
Buse, J. B., Sesti, G., Schmidt, W. E., Montanya, E., Chang, C., Xu, Y., Blonde, L., Rosenstock, J., & for the Liraglutide Effect Action in Diabetes (LEAD)-6 Study Group (2010) · Diabetes Care · doi:10.2337/dc09-2260 · Cited by 177 · see citing works
Bodyweight Changes Associated with Antihyperglycaemic Agents in Type 2 Diabetes Mellitus
Hermansen, K., & Mortensen, L. S. (2007) · Drug Safety · doi:10.2165/00002018-200730120-00005 · Cited by 173 · see citing works
Potts, J. E., Gray, L. J., Brady, E. M., Khunti, K., Davies, M. J., & Bodicoat, D. H. (2015) · PLOS ONE · doi:10.1371/journal.pone.0126769 · Cited by 163 · see citing works
Sex and gender influences on pharmacological response: an overview
Franconi, F., & Campesi, I. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.922866 · Cited by 132 · see citing works
Zinman, B., Schmidt, W. E., Moses, A. C., Lund, N., & Gough, S. C. L. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01493.x · Cited by 119 · see citing works
Medical Therapy for the Patient With Obesity
Bray, G. A., & Ryan, D. H. (2012) · Circulation · doi:10.1161/circulationaha.111.026567 · Cited by 116 · see citing works
Exposure-response analyses of liraglutide 3.0 mg for weight management
Wilding, J. P. H., Overgaard, R. V., Jacobsen, L. V., Jensen, C. B., & le Roux, C. W. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12639 · Cited by 102 · see citing works
The transferability of lipid loci across African, Asian and European cohorts
Kuchenbaecker, K. B., Telkar, N., Reiker, T., Walters, R. G., Lin, K., Eriksson, A., Gurdasani, D., Gilly, A., Southam, L., Tsafantakis, E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12026-7 · Cited by 91 · see citing works
Ostawal, A., Mocevic, E., Kragh, N., & Xu, W. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0180-0 · Cited by 87 · see citing works
Cardiovascular disease risk prediction models: challenges and perspectives
Farzadfar, F. (2019) · The Lancet Global Health · doi:10.1016/s2214-109x(19)30365-1 · Cited by 80 · see citing works
Buysschaert, M., Preumont, V., Oriot, P. R., Paris, I., Ponchon, M., Scarnière, D., & Selvais, P. (2010) · Diabetes & Metabolism · doi:10.1016/j.diabet.2010.03.009 · Cited by 68 · see citing works
Seghieri, G., Anichini, Cosimi, S., Carlo, D., Bellis, D., Franconi, Orsini, P., & Baccetti (2013) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s42729 · Cited by 63 · see citing works
Sex-Gender Differences in Diabetes Vascular Complications and Treatment
Franconi, F., Campesi, I., Occhioni, S., & Tonolo, G. (2012) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/187153012800493512 · Cited by 61 · see citing works
An Overview of the Genetic Structure within the Italian Population from Genome-Wide Data
Gaetano, C. D., Voglino, F., Guarrera, S., Fiorito, G., Rosa, F., Blasio, A. M. D., Manzini, P. M., Dianzani, I., Betti, M., Cusi, D., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043759 · Cited by 55 · see citing works
Poduri, A., Khullar, M., Bahl, A., Sehrawat, B. S., Sharma, Y. P., & Talwar, K. K. (2010) · DNA and Cell Biology · doi:10.1089/dna.2009.1008 · Cited by 53 · see citing works
CHIEFARI, E. D., Tanyolaç, S., Iiritano, S., Sciacqua, A., Capula, C., Arcidiacono, B., Nocera, A., Possidente, K., Baudi, F., Ventura, V., et al. (2013) · Scientific Reports · doi:10.1038/srep01491 · Cited by 52 · see citing works
Self-citationMirabelli, M., CHIEFARI, E. D., Caroleo, P., Vero, R., Brunetti, F. S., Corigliano, D. M., Arcidiacono, B., FOTI, D. P., Puccio, L., & Brunetti, A. (2019) · Journal of Diabetes Research · doi:10.1155/2019/3971060 · Cited by 51 · see citing works
Self-citationFeng, P., Yu, D. M., Chen, L., Chang, B., Ji, Q.-D., Li, S., Zhu, M. J., Ding, S.-H., Zhang, B.-Z., Wang, S.-L., et al. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.136 · Cited by 40 · see citing works
Lapolla, A., Frison, V., Bettio, M., Pos, M. D., Rocchini, P., Panebianco, G., Tadiotto, F., Tos, V. D., D׳Ambrosio, M., Marangoni, A., et al. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.11.015 · Cited by 40 · see citing works
CHIEFARI, E. D., Ventura, V., Capula, C., Randazzo, G., Scorcia, V., Fedele, M., Arcidiacono, B., Nevolo, M. T., Bilotta, F. L., Vitiello, M., et al. (2016) · Scientific Reports · doi:10.1038/srep39429 · Cited by 40 · see citing works
Self-citationPrevention and cure of type 2 diabetes
Pinkney, J. H. (2002) · BMJ · doi:10.1136/bmj.325.7358.232 · Cited by 34 · see citing works
Ramos-López, O., Riezu‐Boj, J. I., Milagro, F. I., Goñi, L., Cuervo, M., & Martínez, J. A. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.11.006 · Cited by 31 · see citing works
Chiefari, E., Capula, C., Vero, A., Oliverio, R., Puccio, L., Liguori, R., Pullano, V., Greco, M., Foti, D., Tirinato, D., et al. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0412 · Cited by 22 · see citing works
Self-citationFrison, V., Simioni, N., Marangoni, A., Balzano, S., Vinci, C., Zenari, L., Moliner, L. D., Tadiotto, F., D’Ambrosio, M., Confortin, L., et al. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0503-4 · Cited by 12 · see citing works
Pharmacogenetics in type 2 diabetes: still a conundrum in clinical practice
Brunetti, A., CHIEFARI, E. D., & FOTI, D. P. (2017) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2017.1316192 · Cited by 8 · see citing works
Self-citationAdult Obesity: Metabolic Syndrome, Diabetes and Non‐Alcoholic Steatohepatitis
Dewan, S., & Wilding, J. P. H. (2005) · doi:10.1002/9780470987087.ch17 · Cited by 3 · see citing works
Gender differences in type 2 diabetes (Italy)
Manicardi, V., Rossi, M. C., Romeo, E. L., Giandalia, A., Calabrese, M., Cimino, E., Antenucci, D., Bollati, P., Volsi, P. L., Maffettone, A., et al. (2016) · Italian Journal of Gender-Specific Medicine · Cited by 3 · see citing works
Flagged first, then by citations
3 of the 49 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Type II diabetes mellitus: a review on recent drug based therapeutics.
Padhi, S., Nayak, A. K., & Behera, A. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110708 · Cited by 726 · see citing works
Pharmacotherapy of obesity: an update on the available medications and drugs under investigation
Chakhtoura, M., Haber, R., Ghezzawi, M., Rhayem, C., Tcheroyan, R., & Mantzoros, C. S. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.101882 · Cited by 462 · see citing works
Mediterranean diet nutrients to turn the tide against insulin resistance and related diseases
Mirabelli, M., Chiefari, E., Arcidiacono, B., Corigliano, D. M., Brunetti, F. S., Maggisano, V., Russo, D., Foti, D. P., & Brunetti, A. (2020) · Nutrients · doi:10.3390/nu12041066 · Cited by 272 · see citing works
“a diabetes prevention pers ctiv , he GLP-1-releasing ffects of PUFAs could be particularly important, g ven th t obes patients have lower GLP-1 responses to oral glucose th n individuals of normal weight, irresp ctive of the glycemic status [52,53].”
BackgroundSelf-citationRentzeperi, E., Pegiou, S., Koufakis, T., Grammatiki, M., & Kotsa, K. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030454 · Cited by 140 · see citing works
GLP-1 and Its Analogs: Does Sex Matter?
Börchers, S., & Skibicka, K. P. (2024) · Endocrinology · doi:10.1210/endocr/bqae165 · Cited by 91 · see citing works
Potential Benefits and Harms of Novel Antidiabetic Drugs During COVID-19 Crisis
Mirabelli, M., CHIEFARI, E. D., Puccio, L., FOTI, D. P., & Brunetti, A. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17103664 · Cited by 63 · see citing works
Self-citationEffect of liraglutide on expression of inflammatory genes in type 2 diabetes
Zobel, E. H., Ripa, R. S., von Scholten, B. J., Rotbain Curovic, V., Kjaer, A., Hansen, T. W., Rossing, P., & Størling, J. (2021) · Scientific Reports · doi:10.1038/s41598-021-97967-0 · Cited by 59 · see citing works
Panganiban, J. A., Kehar, M., Ibrahim, S. H., Hartmann, P., Sood, S., Hassan, S. M., Ramirez, C. M., Kohli, R., Censani, M., Mauney, E. E., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100164 · Cited by 54 · see citing works
Wei, L., Mo, W., Lan, S., Yang, H., Huang, Z., Liang, X., Li, L., Xian, J., Xie, X., Qin, Y., et al. (2022) · Journal of Diabetes Research · doi:10.1155/2022/1861940 · Cited by 42 · see citing works
MASLD: Prevalence, Mechanisms, and Sex-Based Therapies in Postmenopausal Women
Milani, I., Chinucci, M., Leonetti, F., & Capoccia, D. (2025) · Biomedicines · doi:10.3390/biomedicines13040855 · Cited by 38 · see citing works
“However, one study found that, in addition to female sex, a higher baseline BMI was also associated with greater weight loss after treatment with liraglutide [331].”
Mirabelli, M., CHIEFARI, E. D., Tocci, V., Caroleo, P., Giuliano, S., Greco, E. A., Luque, R. M., Puccio, L., FOTI, D. P., Aversa, A., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10050985 · Cited by 37 · see citing works
Self-citationJegier, A., Szalewska, D., Mawlichanów, A., Bednarczyk, T., Eysymontt, Z., Gałaszek, M., Mamcarz, A., Mierzyńska, A., Piotrowicz, E., Piotrowicz, R., et al. (2021) · Kardiologia Polska · doi:10.33963/kp.a2021.0066 · Cited by 40 · see citing works
Bensignor, M. O., Bomberg, E. M., Bramante, C. T., Divyalasya, T. V. S., Hale, P. M., Ramesh, C. K., Rudser, K. D., & Kelly, A. S. (2021) · Pediatric Obesity · doi:10.1111/ijpo.12778 · Cited by 26 · see citing works
Chichura, K. S., Elfers, C., Salameh, T. S., Kamat, V., Chepurny, O. G., McGivney, A., Milliken, B. T., Holz, G. G., Applebey, S. V., Hayes, M. R., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-36178-1 · Cited by 25 · see citing works
Campesi, I., Seghieri, G., & Franconi, F. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.06.007 · Cited by 25 · see citing works
Nesci, V., Russo, E., Arcidiacono, B., Citraro, R., Tallarico, M., Constanti, A., Brunetti, A., Sarro, G. D., & Leo, A. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02062-6 · Cited by 19 · see citing works
Self-citationMedicare Part D Coverage of Anti-obesity Medications: a Call for Forward-Looking Policy Reform
Hernandez, I., Wright, D. R., Guo, J., & Shrank, W. H. (2024) · Journal of General Internal Medicine · doi:10.1007/s11606-023-08416-9 · Cited by 18 · see citing works
Ziebarth, J., & Mainardes, R. M. (2023) · Journal of Thermal Analysis and Calorimetry · doi:10.1007/s10973-022-11909-0 · Cited by 17 · see citing works
Jamalinia, M., Saeian, S., Nikkhoo, N., Nazerian, A., & Lankarani, K. B. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.131 · Cited by 17 · see citing works
Conley, T. E., White, K., Bond, A., Harrison, S. J., McLaughlin, J. T., & Lal, S. (2023) · Frontline Gastroenterology · doi:10.1136/flgastro-2023-102402 · Cited by 15 · see citing works
Block, C. E. M. D., Peleshok, J. C., Wilding, J. P. H., Kwan, A. Y. M., Rasouli, N., Maldonado, J. M., Wysham, C., Liu, M., Aleppo, G., & Benneyworth, B. D. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01660-0 · Cited by 15 · see citing works
Dileo, E., Saba, F., Parasiliti‐Caprino, M., Rosso, C., & Bugianesi, E. (2025) · Nutrients · doi:10.3390/nu17030477 · Cited by 12 · see citing works
Koike, M., Saito, H., Kohno, G., Takubo, M., Watanabe, K., & Ishihara, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111463 · Cited by 12 · see citing works
Sex-Differences in Response to Treatment with Liraglutide 3.0 mg
(2024) · doi:10.3390/jcm13123369 · Cited by 11 · see citing works
New-onset diabetes in COVID-19: The molecular pathogenesis
Wihandani, D. M., Purwanta, M. L. A., Mulyani, W. R. W., Putra, I. W. A. S., & Supadmanaba, I. G. P. (2023) · Biomedicine · doi:10.37796/2211-8039.1389 · Cited by 11 · see citing works
The Genetic Blueprint of Obesity: From Pathogenesis to Novel Therapies
Tonin, G., Eržen, S., Mlinarič, Z., Jurišić‐Eržen, D., Horvat, S., Kunej, T., & Klen, J. (2025) · Obesity Reviews · doi:10.1111/obr.13978 · Cited by 11 · see citing works
Hoffmann, K., Michalak, M., & Paczkowska, A. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s531697 · Cited by 9 · see citing works
Recent advancements in pharmacological strategies to modulate energy balance for combating obesity.
Pati, B., Sendh, S., Sahu, B., Pani, S., Jena, N., & Bal, N. (2023) · RSC Medicinal Chemistry · doi:10.1039/d3md00107e · Cited by 10 · see citing works
Xia, X., Xue, S., Yang, G., Yu, L. J., Liu, H., Chen, C., & Li, L. (2021) · PeerJ · doi:10.7717/peerj.11869 · Cited by 9 · see citing works
Zhou, F., Jiang, L., Guo, J., Fan, Y., Pan, Q., Li, T., Sun, X., & Li, P. (2023) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223231161516 · Cited by 7 · see citing works
Kadowaki, T., Lee, S. Y., Ogawa, W., Nishida, T., Overvad, M., Tobe, K., Yamauchi, T., & Lim, S. K. (2024) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2025.01.002 · Cited by 6 · see citing works
Effectiveness, Safety, and Patient Satisfaction of Liraglutide in Type 2 Diabetic Patients
Zameer, R., Kamin, M., Raja, U. Y., Wahab, M. U., Ishtiaq, O., Raashid, K., Ahmed, N., & Rehman, A. U. (2020) · Cureus · doi:10.7759/cureus.9937 · Cited by 5 · see citing works
Gavigan, C., & Donner, T. W. (2023) · Journal of Diabetes Research · doi:10.1155/2023/9972132 · Cited by 4 · see citing works
The role of PYY in improving insulin resistance
Liu, C., Na, R., Zhang, H., & Ma, J. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1784709 · Cited by 4 · see citing works
Alhussein, N. A., Mahzari, M. M., Aljumaie, N. M., Alosaimi, M., Almansouf, A. S., & Alkahtani, F. (2021) · Cureus · doi:10.7759/cureus.18155 · Cited by 4 · see citing works
A Study on Weight Loss Cause as per the Side Effect of Liraglutide
Yu, J. S., Lee, J., Lee, S., Cho, J., & Kim, H. (2022) · Cardiovascular Therapeutics · doi:10.1155/2022/5201684 · Cited by 4 · see citing works
Kimura, T., Kubo, M., Takahashi, K., Wamata, R., Iwamoto, Y., Iwamoto, H., Katakura, Y., Sanada, J., Fushimi, Y., Shimoda, M., et al. (2024) · Journal of Diabetes Research · doi:10.1155/2024/5880589 · Cited by 4 · see citing works
Wang, L., Tang, Y., He, H., & Wei, W. (2021) · Acta Cirúrgica Brasileira · doi:10.1590/acb360207 · Cited by 4 · see citing works
Alshanwani, A. R., Kashour, T., & Badr, A. M. (2021) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530321666210809153558 · Cited by 6 · see citing works
Gender-Difference in Response to Treatment with Liraglutide 3.0 mg
Milani, I., Guarisco, G., Chinucci, M., Gaita, C., Leonetti, F., & Capoccia, D. (2024) · doi:10.20944/preprints202405.0568.v1 · Cited by 11 · see citing works
Al‐Samiry, A. H., Mohammed, S. I., & Mubder, N. (2024) · Al-Rafidain Journal of Medical Sciences · doi:10.54133/ajms.v6i1.413 · Cited by 3 · see citing works
Iuliano, S., Greco, E. A., Mirabelli, M., CHIEFARI, E. D., Caroleo, P., Puccio, L., Giuliano, S., FOTI, D. P., Brunetti, A., & Aversa, A. (2022) · Minerva Endocrinology · doi:10.23736/s2724-6507.22.03691-0 · Cited by 3 · see citing works
Self-citationCase report of an angiosarcoma of the abdominal wall during liraglutide injections
Bergeron, É., Dami, M., Do, X. V., Vallee, C., & Noujaim, J. C. (2022) · International Journal of Surgery Case Reports · doi:10.1016/j.ijscr.2022.107444 · Cited by 2 · see citing works
Insights into the World of MicroRNAs
Greco, M., CHIEFARI, E. D., Mirabelli, M., Salatino, A., Pullano, S. A., Aversa, A., FOTI, D. P., & Brunetti, A. (2022) · Biomarkers in disease · doi:10.1007/978-3-031-08014-2_34 · Cited by 2 · see citing works
Self-citationSilva‐Nunes, J., Nascimento, E., Louro, J., Dores, J. M., Laginha, T., Gonçalves-Ferreira, A., Alves, M., Souto, S. B., Cunha, N. C., Pina, E., et al. (2022) · Metabolites · doi:10.3390/metabo12111121 · Cited by 2 · see citing works
Insights into the World of MicroRNAs
Greco, M., CHIEFARI, E. D., Mirabelli, M., Salatino, A., Pullano, S. A., Aversa, A., FOTI, D. P., & Brunetti, A. (2022) · Biomarkers in disease · doi:10.1007/978-3-030-81303-1_34-1 · Cited by 1 · see citing works
Self-citationAlnageeb, H., Qaidy, A. A., ALakkad, A., Murad, R. A., Mahgoub, I., Mardini, M., Shalabi, H. E., Rabih, A. M. A., & Gopakumar, A. (2023) · Advances in Research · doi:10.9734/air/2023/v24i2936 · Cited by 1 · see citing works
The alpha-7 nicotinic acetylcholine receptor agonist PHA-543613 reduces food intake in male rats
DiBrog, A. M., Kern, K. A., Demieri, E., & Mietlicki‐Baase, E. G. (2024) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2024.173723 · Cited by 1 · see citing works
ANALEPTIC APPLICATIONS OF PEPTIDES
Kwatra, B., Zafar, J., Choudhary, M., Akhtar, N., & Golani, T. (2021) · International Journal of Medical and Biomedical Studies · doi:10.32553/ijmbs.v5i1.1671 · Cited by 1 · see citing works
A Partial Phenotype of adFNDI Related to the Signal Peptide c.55G>A Variant of the AVP Gene
Tocci, V., Mirabelli, M., Giuliano, S., CHIEFARI, E. D., Knudsen, J. H., Kvistgaard, H., Torre, D. L., Aversa, A., FOTI, D. P., Christensen, J., et al. (2021) · Endocrines · doi:10.3390/endocrines2010004 · Cited by 1 · see citing works
Self-citationXiao, S., Yang, Y., Liu, Y., & Zhu, J. (2021) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-021-00974-0
Alsafwani, D. M., Alotaibi, H. N., Alzaid, J. A., Alghamdi, A., & Almakhaita, H. M. (2022) · Cureus · doi:10.7759/cureus.23554
RetractedUllah, S., Hussain, A., Kanwal, S., Jamal, A. A., & Faisal, M. (2022) · Journal of Medical Sciences · doi:10.52764/jms.22.30.4.15
Use of liraglutide in the patient with obesity and type 2 diabetes mellitus: a literature review
Cancino, J. A. D., Álvarez, C. J. S., & Ramírez, K. A. Z. (2023) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20232577
Efeitos da liraglutida em pacientes com diabetes tipo 2 e obesidade
de Fraga, B. C., & Deuner, M. C. (2024) · Revista JRG de Estudos Acadêmicos · doi:10.55892/jrg.v7i14.1156
AlRashidi, A., Alarfaj, R. M., Ruqaib, A. M. A., Masuadi, E., AlFaraj, M., Al‐Saleh, Y., AlEnezi, R., Mahzari, M. M., & Aljulifi, M. Z. (2024) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/jpbs.jpbs_473_24
Lipska, D., Suvitaival, T., Kienle, S. M., von Scholten, B. J., Ripa, R. S., Zobel, E. H., Størling, J., Blond, M. B., Ahluwalia, T. S., Hansen, T. W., et al. (2026) · medRxiv · doi:10.64898/2026.07.22.26358565
Terrell, K. A., Lage, M. J., Valentine, W. J., Paik, J. S., & Boye, K. S. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03753-7
Bawadi, H. A., Abuhijleh, H., Nofal, M., Zakaria, Z. Z., & Al‐Asmakh, M. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70338
- Authors
- Mirabelli, M., Chiefari, E., Caroleo, P., Arcidiacono, B., Corigliano, D. M., Giuliano, S., Brunetti, F. S., Tanyolaç, S., Foti, D. P., Puccio, L., & Brunetti, A.
- Affiliations
- Magna Graecia University (IT)
- Azienda Ospedaliera Pugliese Ciaccio (IT)
- Biruni University (TR)
- Corresponding author
- Brunetti, Antonio
- ORCID
- Venue
- International Journal of Environmental Research and Public Health
- Publisher
- MDPI AG
- Published
- 2019-12-27
- Volume
- 17
- Issue
- 1
- Pages
- 207
- ISSN
- 1660-4601 (ISSN-L)
- PMC
- PMC6981922
- OpenAlex
- W2998154547
- Cited by
- 61
- References
- 49
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 9 · 2023: 11 · 2022: 10 · 2021: 16 · 2020: 5
- FWCI
- 6.29
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Environmental Research and Public Health (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- European Commission and Regione Calabria. (FESR FSE 2014-2020)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- liraglutide, type 2 diabetes, GLP-1 receptor agonists, weight loss, glycemic control, long-term treatment effectiveness, overweight and obesity, sex differences, cardiovascular risk, myocardial infarction, HbA1c, fasting blood glucose, lipid profile
- MeSH terms
- Liraglutide, Body Weight, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Retrospective Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
